Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Total Debt (2018 - 2025)

Arcturus Therapeutics Holdings' Total Debt history spans 7 years, with the latest figure at $15.0 million for Q1 2025.

  • For Q1 2025, Total Debt changed N/A year-over-year to $15.0 million; the TTM value through Mar 2025 reached $15.0 million, changed N/A, while the annual FY2022 figure was $60.7 million, 3.89% down from the prior year.
  • Total Debt reached $15.0 million in Q1 2025 per ARCT's latest filing, down from $20.0 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $63.5 million in Q1 2022 to a low of $15.0 million in Q1 2025.
  • Average Total Debt over 4 years is $52.8 million, with a median of $61.0 million recorded in 2021.
  • Peak YoY movement for Total Debt: skyrocketed 318.07% in 2021, then plummeted 66.52% in 2023.
  • A 4-year view of Total Debt shows it stood at $63.1 million in 2021, then dropped by 3.89% to $60.7 million in 2022, then plummeted by 67.03% to $20.0 million in 2023, then fell by 25.0% to $15.0 million in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Total Debt are $15.0 million (Q1 2025), $20.0 million (Q3 2023), and $60.7 million (Q4 2022).